Literature DB >> 17899444

Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients.

Ana Bronić1, Goran Ferencak, Renata Zadro, Ana Stavljenić-Rukavina, Robert Bernat.   

Abstract

Arterial thrombosis is the major reason for severe complications of coronary artery disease (CAD). Recently it has been suggested that the FXIII-A Val34Leu polymorphism, affecting clot stability, provides protection against thrombosis. Results published up to date implicate that there is a significant correlation between geographical area and the Leu34 allele prevalence and that its contribution to arterial thrombosis is different in different populations. The purpose of this study was to determine frequency of Leu34 allele in Croatian subjects as well as to estimate its association with a CAD. FXIII-A Val34Leu genotyping was carried out by real-time PCR method on the LightCycler using melting curve analysis with forward 5'-AACTTCCAGGACCGGCTTT-3' and reverse 5'-ACCCAGAGTGGTGGGGAA-3' primers. The Leu34 allele frequency in studied Croatian subjects was 24.3%. No significant differences were found in the prevalence of FXIII-A Val34Leu genotype or Leu34 allele distribution between studied subjects (P > 0.05). Carriage of the Leu34 allele was not significantly associated with CAD or MI risk reduction (P > 0.05). This is the first report that studies the prevalence of the Leu34 allele frequency in Croatian subjects and our results suggest that possession of the Leu 34 alele does not provide protection against MI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899444     DOI: 10.1007/s11033-007-9144-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  32 in total

1.  The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.

Authors:  A Elbaz; O Poirier; S Canaple; F Chédru; F Cambien; P Amarenco
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Ethnic heterogeneity of the factor XIII Val34Leu polymorphism.

Authors:  F A Attié-Castro; M A Zago; J Lavinha; J Elion; L Rodriguez-Delfin; J F Guerreiro; R F Franco
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

3.  Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males.

Authors:  U Wartiovaara; M Perola; H Mikkola; K Tötterman; V Savolainen; A Penttilä; P J Grant; M J Tikkanen; E Vartiainen; P J Karhunen; L Peltonen; A Palotie
Journal:  Atherosclerosis       Date:  1999-02       Impact factor: 5.162

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Genetic polymorphisms and coronary artery disease in the south of France.

Authors:  I Canavy; M Henry; P E Morange; L Tiret; O Poirier; A Ebagosti; M Bory; I Juhan-Vague
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

Review 6.  Haemostatic genetic risk factors in arterial thrombosis.

Authors:  R E Simmonds; J Hermida; S M Rezende; D A Lane
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

Review 7.  Physiopathology and regulation of factor XIII.

Authors:  A Ichinose
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

8.  Association of a common polymorphism in the factor XIII gene with myocardial infarction.

Authors:  H P Kohler; M H Stickland; N Ossei-Gerning; A Carter; H Mikkola; P J Grant
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

9.  No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.

Authors: 
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

10.  The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity.

Authors:  S Kangsadalampai; P G Board
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more
  5 in total

1.  Single nucleotide polymorphisms of the purinergic 1 receptor are not associated with myocardial infarction in a Latvian population.

Authors:  Vita Ignatovica; Gustavs Latkovskis; Raitis Peculis; Kaspars Megnis; Helgi B Schioth; Iveta Vaivade; Davids Fridmanis; Valdis Pirags; Andrejs Erglis; Janis Klovins
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

2.  FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype--phenotype case control study.

Authors:  Johanne Silvain; Ana Pena; Jean-Baptiste Vignalou; Jean-Sébastien Hulot; Sophie Galier; Guillaume Cayla; Anne Bellemain-Appaix; Olivier Barthélémy; Farzin Beygui; Claire Bal-dit-Sollier; Ludovic Drouet; John W Weisel; Gilles Montalescot; Jean-Phillippe Collet
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

3.  Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction.

Authors:  Waqas Ahmed; Meera Malik; Imran Saeed; Amina Ali Khan; Ahmed Sadeque; Umar Kaleem; Nuzhat Ahmed; Muhammad Ajmal; Maleeha Azam; Raheel Qamar
Journal:  Mol Biol Rep       Date:  2010-11-17       Impact factor: 2.316

4.  Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.

Authors:  Ana Bronić; Goran Ferenčak; Robert Bernat; Jasna Leniček-Krleža; Jerka Dumić; Sanja Dabelić
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

5.  Lack of Associations Between PAI-1 and FXIII Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis.

Authors:  Beata Sarecka-Hujar; Ilona Kopyta; Michał Skrzypek
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.